FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2592558093> ?p ?o ?g. }

• W2592558093 endingPage "05" @default.
• W2592558093 startingPage "S1" @default.
• W2592558093 abstract "Abstract Background: Extending adjuvant endocrine therapy (tx) after 5 yrs of tamoxifen (Tam) with either Tam or an AI improves disease-free survival (DFS) in early-stage breast cancer (BC). However, optimal duration of adjuvant AI tx beyond 5 yrs is unknown. NSABP B-42 aimed to determine whether 5 yrs of letrozole (L) v placebo (P) improves DFS in patients (pts) who have completed 5 yrs of hormonal tx (with either AI or TAM→AI). Methods: Postmenopausal pts with stage I-III, hormone-receptor (+) BC, disease-free after 5 yrs of either AI or Tam for ≤3 years→AI for the remainder of 5 yrs, were randomized to L 2.5 mg or P daily for an additional 5 yrs. Stratification was by pathological nodal status, prior adjuvant Tam or not, and baseline dexa T scores (&gt;-2.0, ≤-2.0 SD). Primary endpoint was DFS including local, regional, distant recurrence (DR), second primary cancers, and deaths from any cause as first event. Secondary endpoints included overall survival (OS), BC-free interval (BCFI including recurrence or contralateral BC as first event), DR, osteoporotic fractures (OF), and arterial thrombotic (AT) events. Differences in DFS, OS, BCFI, DR, OF, and AT between L and P were assessed by the stratified log-rank tests and Cox proportional hazards models. Statistical significance level for DFS was set at 0.0418 as per statistical plan. Results: From 9/06-1/10, 3966 pts were randomized (34% were &lt;60 yrs, 57% were node-negative, 39% received prior TAM, 14% were HER-2 neu positive). Median follow-up for 3923 pts included in efficacy analyses was 6.9 years. As of 8/16, 631 DFS events occurred (L=292, P=339); L did not result in statistically significant increase in DFS v P (HR=0.85; 95% CI 0.73, 0.999; P=0.048), even after adjusting for age or surgery type; 7-yr DFS was L=84.7% and P=81.3%. There were no significant interactions between treatment and stratification variables. 310 deaths occurred (L=164, P=146); there was no statistically significant difference in OS with L v P (HR=1.15, 95% CI 0.92, 1.44; P=0.22); 7-yr OS was L=91.8% and P=92.3%; 306 BCFI events occurred (L=127, P=179); L v P resulted in a statistically significant 29% decrease in BCFI events (HR=0.71, 95% CI 0.56, 0.89; P=0.003); 7-yr cumulative incidence (CIn) of BCFI was L=6.7% v P=10%; 175 DRs occurred (L=73, P=102); L v P resulted in a statistically significant 28% reduction in DR (HR=0.72, 95% CI 0.53, 0.97; P=0.03). There were 169 OF (L=91, P=78). There were no significant differences in time to OF with L v P (P=0.27). CIn of OF through 7 yrs was L=5.4% v P=4.8%. There were 127 AT events (L=69, P=58). Treatment with L did not result in an overall statistically significant increase in AT events compared to P (P=0.33). CIn of AT through 7 yrs was L=3.9% v P=3.3%. Conclusions: After 5 yrs of an AI or TAM→AI, the beneficial effect of extended tx with 5 yrs of L on DFS did not reach statistical significance. There was no significant improvement in OS with L but L provided a significant improvement in BCFI and DR. Support: U10CA180868, -180822; UG1CA189867; Novartis. Citation Format: Mamounas EP, Bandos H, Lembersky BC, Geyer, Jr CE, Fehrenbacher L, Graham ML, Chia SL, Brufsky AM, Hennessy BT, Soori GS, Dakil SR, Seay TE, Wade, III JL, McCarron EC, Paik S, Swain SM, Wickerham DL, Wolmark N. A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy (tx) with letrozole (L) in postmenopausal women with hormone-receptor (+) breast cancer (BC) who have completed previous adjuvant tx with an aromatase inhibitor (AI): Results from NRG Oncology/NSABP B-42 [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr S1-05." @default.
• W2592558093 created "2017-03-16" @default.
• W2592558093 creator A5008296741 @default.
• W2592558093 creator A5010529280 @default.
• W2592558093 creator A5018295528 @default.
• W2592558093 creator A5033033849 @default.
• W2592558093 creator A5034389966 @default.
• W2592558093 creator A5039079586 @default.
• W2592558093 creator A5051850175 @default.
• W2592558093 creator A5052775857 @default.
• W2592558093 creator A5055013606 @default.
• W2592558093 creator A5055995443 @default.
• W2592558093 creator A5059990280 @default.
• W2592558093 creator A5063900632 @default.
• W2592558093 creator A5067203408 @default.
• W2592558093 creator A5074479466 @default.
• W2592558093 creator A5077640655 @default.
• W2592558093 creator A5078571653 @default.
• W2592558093 creator A5085590393 @default.
• W2592558093 creator A5087850212 @default.
• W2592558093 date "2017-02-15" @default.
• W2592558093 modified "2023-10-01" @default.
• W2592558093 title "Abstract S1-05: A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy (tx) with letrozole (L) in postmenopausal women with hormone-receptor (+) breast cancer (BC) who have completed previous adjuvant tx with an aromatase inhibitor (AI): Results from NRG Oncology/NSABP B-42" @default.
• W2592558093 doi "https://doi.org/10.1158/1538-7445.sabcs16-s1-05" @default.
• W2592558093 hasPublicationYear "2017" @default.
• W2592558093 type Work @default.
• W2592558093 sameAs 2592558093 @default.
• W2592558093 citedByCount "27" @default.
• W2592558093 countsByYear W25925580932017 @default.
• W2592558093 countsByYear W25925580932018 @default.
• W2592558093 countsByYear W25925580932019 @default.
• W2592558093 countsByYear W25925580932020 @default.
• W2592558093 countsByYear W25925580932021 @default.
• W2592558093 countsByYear W25925580932022 @default.
• W2592558093 crossrefType "journal-article" @default.
• W2592558093 hasAuthorship W2592558093A5008296741 @default.
• W2592558093 hasAuthorship W2592558093A5010529280 @default.
• W2592558093 hasAuthorship W2592558093A5018295528 @default.
• W2592558093 hasAuthorship W2592558093A5033033849 @default.
• W2592558093 hasAuthorship W2592558093A5034389966 @default.
• W2592558093 hasAuthorship W2592558093A5039079586 @default.
• W2592558093 hasAuthorship W2592558093A5051850175 @default.
• W2592558093 hasAuthorship W2592558093A5052775857 @default.
• W2592558093 hasAuthorship W2592558093A5055013606 @default.
• W2592558093 hasAuthorship W2592558093A5055995443 @default.
• W2592558093 hasAuthorship W2592558093A5059990280 @default.
• W2592558093 hasAuthorship W2592558093A5063900632 @default.
• W2592558093 hasAuthorship W2592558093A5067203408 @default.
• W2592558093 hasAuthorship W2592558093A5074479466 @default.
• W2592558093 hasAuthorship W2592558093A5077640655 @default.
• W2592558093 hasAuthorship W2592558093A5078571653 @default.
• W2592558093 hasAuthorship W2592558093A5085590393 @default.
• W2592558093 hasAuthorship W2592558093A5087850212 @default.
• W2592558093 hasConcept C121608353 @default.
• W2592558093 hasConcept C126322002 @default.
• W2592558093 hasConcept C142724271 @default.
• W2592558093 hasConcept C143998085 @default.
• W2592558093 hasConcept C168563851 @default.
• W2592558093 hasConcept C203092338 @default.
• W2592558093 hasConcept C204787440 @default.
• W2592558093 hasConcept C27081682 @default.
• W2592558093 hasConcept C2777176818 @default.
• W2592558093 hasConcept C2778311097 @default.
• W2592558093 hasConcept C2778812593 @default.
• W2592558093 hasConcept C530470458 @default.
• W2592558093 hasConcept C71924100 @default.
• W2592558093 hasConceptScore W2592558093C121608353 @default.
• W2592558093 hasConceptScore W2592558093C126322002 @default.
• W2592558093 hasConceptScore W2592558093C142724271 @default.
• W2592558093 hasConceptScore W2592558093C143998085 @default.
• W2592558093 hasConceptScore W2592558093C168563851 @default.
• W2592558093 hasConceptScore W2592558093C203092338 @default.
• W2592558093 hasConceptScore W2592558093C204787440 @default.
• W2592558093 hasConceptScore W2592558093C27081682 @default.
• W2592558093 hasConceptScore W2592558093C2777176818 @default.
• W2592558093 hasConceptScore W2592558093C2778311097 @default.
• W2592558093 hasConceptScore W2592558093C2778812593 @default.
• W2592558093 hasConceptScore W2592558093C530470458 @default.
• W2592558093 hasConceptScore W2592558093C71924100 @default.
• W2592558093 hasIssue "4_Supplement" @default.
• W2592558093 hasLocation W25925580931 @default.
• W2592558093 hasOpenAccess W2592558093 @default.
• W2592558093 hasPrimaryLocation W25925580931 @default.
• W2592558093 hasRelatedWork W1957203373 @default.
• W2592558093 hasRelatedWork W1971410221 @default.
• W2592558093 hasRelatedWork W1977552076 @default.
• W2592558093 hasRelatedWork W1984699041 @default.
• W2592558093 hasRelatedWork W2003583183 @default.
• W2592558093 hasRelatedWork W2043253988 @default.
• W2592558093 hasRelatedWork W2061831761 @default.
• W2592558093 hasRelatedWork W2068466046 @default.
• W2592558093 hasRelatedWork W2126511903 @default.
• W2592558093 hasRelatedWork W2172254302 @default.
• W2592558093 hasVolume "77" @default.
• W2592558093 isParatext "false" @default.
• W2592558093 isRetracted "false" @default.
• W2592558093 magId "2592558093" @default.
• W2592558093 workType "article" @default.